Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 1
1968 3
1969 2
1970 5
1971 7
1972 7
1973 3
1974 8
1975 4
1976 6
1977 4
1978 10
1979 8
1980 14
1981 9
1982 8
1983 10
1984 14
1985 14
1986 24
1987 20
1988 30
1989 26
1990 29
1991 38
1992 26
1993 38
1994 48
1995 57
1996 61
1997 42
1998 51
1999 52
2000 81
2001 94
2002 71
2003 77
2004 92
2005 89
2006 81
2007 58
2008 60
2009 42
2010 37
2011 25
2012 26
2013 32
2014 33
2015 18
2016 30
2017 26
2018 26
2019 16
2020 15
2021 18
2022 19
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

1,655 results
Results by year
Filters applied: . Clear all
Page 1
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J; WHI Investigators. Manson JE, et al. JAMA. 2017 Sep 12;318(10):927-938. doi: 10.1001/jama.2017.11217. JAMA. 2017. PMID: 28898378 Free PMC article. Clinical Trial.
INTERVENTIONS: Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo (n = 8102) for 5.6 years (median) or CEE alone (n = 5310) vs placebo (n = 5429) for 7.2 years (median). ...
INTERVENTIONS: Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo ( …
Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera.
Halpern V, Brache V, Taylor D, Lendvay A, Cochón L, Jensen JT, Dorflinger LJ. Halpern V, et al. Fertil Steril. 2021 Apr;115(4):1035-1043. doi: 10.1016/j.fertnstert.2020.11.002. Epub 2021 Jan 21. Fertil Steril. 2021. PMID: 33485608 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after a single subcutaneous injection in the abdomen of 150 or 300 mg Depo-Provera and compare results to two injections of Depo-SubQ Provera 104 given 3 months apart. ...MAIN O …
OBJECTIVE: To evaluate the pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after a single subcutaneous injection …
Evaluation of the Safety and Efficacy of Ormeloxifene, a Selective Estrogen Receptor Modulator and Medroxyprogesterone Acetate in Women with Non-Structural Abnormal Uterine Bleeding: A Randomized Clinical Trial.
Mir SA, Ara R, Amin F, Malik A, Hamid L, Ali T, Bader GN, Wani SUD, Almuqbil M, Alshehri S, Alshehri AM, Shakeel F. Mir SA, et al. Medicina (Kaunas). 2022 Oct 22;58(11):1503. doi: 10.3390/medicina58111503. Medicina (Kaunas). 2022. PMID: 36363460 Free PMC article. Clinical Trial.
The present study aims to compare the cost-effectiveness, safety, efficacy, and health-related quality of life of ormeloxifene with medroxyprogesterone acetate in women with non-structural abnormal uterine bleeding. ...Health-related quality of life improved in the ormelox …
The present study aims to compare the cost-effectiveness, safety, efficacy, and health-related quality of life of ormeloxifene with medro …
Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial.
Singata-Madliki M, Carayon-Lefebvre d'Hellencourt F, Lawrie TA, Balakrishna Y, Hofmeyr GJ. Singata-Madliki M, et al. Int J Gynaecol Obstet. 2021 Aug;154(2):256-262. doi: 10.1002/ijgo.13594. Epub 2021 Mar 2. Int J Gynaecol Obstet. 2021. PMID: 33448029 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the effects of depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel (LNG) implant, and copper intrauterine device (IUD) on mood and sexual function. ...
OBJECTIVE: To compare the effects of depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel (LNG) implant, and copper intrauteri …
A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction.
Said S, Omar K, Koetsawang S, Kiriwat O, Srisatayapan Y, Kazi A, Ajmal F, Wynter HH, Pretnar-Darovec A, Benitez IB, et al. Said S, et al. Contraception. 1986 Sep;34(3):223-35. doi: 10.1016/0010-7824(86)90004-1. Contraception. 1986. PMID: 2947777 Clinical Trial.
Two dosages of depot-medroxyprogesterone acetate (DMPA), 100 mg and 150 mg given every 90 days, were compared in two groups of women with regard to effectiveness, reported complaints and reasons for discontinuation. ...
Two dosages of depot-medroxyprogesterone acetate (DMPA), 100 mg and 150 mg given every 90 days, were compared in two groups of women …
Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report.
[No authors listed] [No authors listed] Contraception. 1983 Jul;28(1):1-20. doi: 10.1016/s0010-7824(83)80002-x. Contraception. 1983. PMID: 6226488 Clinical Trial.
Final results are presented from a two-year WHO multinational comparative trial of three regimens: depot-medroxyprogesterone acetate (DMPA) given at 90-day intervals, norethisterone enanthate (NET-EN) given at 60-day intervals for the entire study period (NET-EN (60-day)), …
Final results are presented from a two-year WHO multinational comparative trial of three regimens: depot-medroxyprogesterone acetate …
A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction.
Said S, Omar K, Koetsawang S, Kiriwat O, Srisatayapan Y, Kazi A, Ajmal F, Wynter HH, Pretnar-Darovec A, Benitez IB. Said S, et al. Contraception. 1987 Jun;35(6):591-610. doi: 10.1016/s0010-7824(87)80019-7. Contraception. 1987. PMID: 2959448 Clinical Trial.
A multicentered phase III clinical trial was conducted in seven countries to compare two dosages of depot-medroxyprogesterone acetate (DMPA), 100mg and 150mg, given every 90 days. ...
A multicentered phase III clinical trial was conducted in seven countries to compare two dosages of depot-medroxyprogesterone acetate …
Treatment of advanced breast cancer with progestins.
Løber J, Rose C, Salimtschik M, Mouridsen HT. Løber J, et al. Acta Obstet Gynecol Scand Suppl. 1981;101:39-46. doi: 10.3109/00016348109157810. Acta Obstet Gynecol Scand Suppl. 1981. PMID: 7030000 Review.
Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial.
Mittal M, McEniery C, Supramaniam PR, Cardozo L, Savvas M, Panay N, Hamoda H. Mittal M, et al. Maturitas. 2022 Jul;161:18-26. doi: 10.1016/j.maturitas.2022.01.012. Epub 2022 Feb 2. Maturitas. 2022. PMID: 35688490 Clinical Trial.
OBJECTIVE: To compare the difference between micronised progesterone (MP) and medroxyprogesterone acetate (MPA) in combination with transdermal oestradiol (t-E(2)) on cardiovascular disease (CVD) risk markers in women diagnosed with an early menopause and premature ovarian …
OBJECTIVE: To compare the difference between micronised progesterone (MP) and medroxyprogesterone acetate (MPA) in combination with t …
The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?
Wells G, Herrington DM. Wells G, et al. Drugs Aging. 1999 Dec;15(6):419-22. doi: 10.2165/00002512-199915060-00001. Drugs Aging. 1999. PMID: 10641952 Review.
Of the 2763 women enrolled, 1380 were randomised to receive 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone daily (Prempro) and 1383 were randomised to receive a placebo. ...Until further data are available, clinicians should not use estrogen plus …
Of the 2763 women enrolled, 1380 were randomised to receive 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone …
1,655 results